MedTrace Logo

A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

NCT06825416 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1166

Last updated 2026-04-13

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty.

Conditions

  • Prevention of Arterial and Venous Thrombosis

Interventions

DRUG

SHR-2004 injection

SHR-2004 injection in low dose.

DRUG

SHR-2004 injection

SHR-2004 injection in high dose.

DRUG

Enoxaparin sodium injection

Enoxaparin sodium injection.

DRUG

Enoxaparin sodium injection placebo

Enoxaparin sodium injection placebo.

DRUG

SHR-2004 placebo

SHR-2004 placebo in low dose.

DRUG

SHR-2004 placebo

SHR-2004 placebo in high dose.

Sponsors & Collaborators

  • Beijing Suncadia Pharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-16
Primary Completion
2026-02-15
Completion
2026-04-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06825416 on ClinicalTrials.gov